Login to Your Account

Financings Roundup

Vasopharm Gets $7M to Prep for Pivotal Brain Injury Trial

By Cormac Sheridan
Staff Writer

Tuesday, June 25, 2013
Vasopharm GmbH raised €5 million (US$6.5 million) in new investment to fund preparations for a Phase III trial of VAS203, an allosteric inhibitor of nitric oxide (NO) synthase in development for treating traumatic brain injury (TBI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription